Stacor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stacor

Quick Facts

Property Description
Active ingredient Atorvastatin Calcium
Form Film-coated tablets
Pharmacological class HMG-CoA reductase inhibitor (Statin)
General purpose Lipid-lowering agent
Origin Synthetic

What Kind of Medicine is Stacor, and What is its Class?

Stacor is a prescription-only pharmaceutical agent featuring the active compound Atorvastatin. It belongs to the HMG-CoA reductase inhibitors therapeutic class, more commonly known as the statins. This classification is clinically recognized for its essential role in modulating the body’s endogenous production of cholesterol.

The drug is a single-ingredient product, and its core identity is defined by its use of Atorvastatin, which is distinguished within the statin class for its efficacy in achieving high-intensity reduction of blood lipids. The medicine is synthetic in origin, ensuring a precise, standardized formulation. The primary mechanism involves the selective competitive inhibition of the HMG-CoA reductase enzyme, which is the rate-limiting step in the liver's synthesis of sterols.

Composition, Form, and General Purpose

Stacor is supplied as a film-coated tablet designed for oral administration, utilizing the active chemical substance Atorvastatin Calcium. The tablet preparation ensures a stable and controlled delivery of the lipid-lowering agent into the systemic circulation.

The overall purpose of Stacor is to function as a potent hypolipidemic agent, reducing high concentrations of fats in the bloodstream, particularly Low-Density Lipoprotein (LDL) cholesterol and Triglycerides. The clinical benefit of this action is the optimization of the patient's lipid profile, a strategy frequently employed to mitigate cardiovascular risks associated with chronic lipid elevation. Maintaining optimized lipid levels is affirmed by major health organizations as vital for long-term health.

Regulatory References

  1. Atorvastatin: MedlinePlus Drug Information
  2. Cardiovascular disease: risk assessment and reduction, including lipid modification - NICE

What side effects are possible with Stacor?

Possible Side Effects and Safety Information

The safety profile of Stacor (Atorvastatin) is formally classified by regulatory authorities, highlighting adverse reactions across several body systems, primarily focusing on musculoskeletal and hepatic safety concerns. Side effects are categorized by their reported frequency in clinical trials, ranging from common to rare events.


Official Adverse Reaction Classification

Adverse reactions classified as Common (occurring in 1/100 to 1/10 patients) in regulatory documents include nasopharyngitis, arthralgia (joint pain), pain in extremity, diarrhea, and urinary tract infection. Effects are grouped into System-Organ Classes such as Infections, Musculoskeletal, Gastrointestinal, and Nervous System disorders.


Serious Safety Concerns and Risk Factors

The regulatory label documents the potential for serious adverse reactions, including Rhabdomyolysis, a severe muscle condition that can lead to acute renal failure, and significant liver injury with associated clinical symptoms. The risk of muscle-related adverse reactions is noted to be linked to the dosage level and is heightened by concurrent use with certain other medications.

Specific contraindications formally prohibit Stacor's use in individuals with active liver disease and during pregnancy or lactation. Predisposing risk factors for muscle toxicity, such as advanced age (ge 65 years), renal impairment, and uncontrolled hypothyroidism, are explicitly identified in the prescribing information. Furthermore, cognitive effects like memory loss or confusion, when reported, are generally noted to be reversible upon discontinuation of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope

Official regulatory experience with acute Atorvastatin (Stacor) overdose is limited, and no specific acute symptom cluster has been formally documented. The primary focus of overdose management is the potential for serious, delayed effects on two physiological systems: the skeletal muscle system and the hepatic system.

Immediate medical help must be sought for any suspected overdose. This action is critical because official guidance requires urgent assessment, and the therapeutic approach is limited to symptomatic and supportive measures, as no specific antidote is known.

Overdose Classifications

While not formally classified by acute severity, the critical, life-threatening risk is the potential for rhabdomyolysis, a severe muscle injury that can lead to acute renal failure. This risk increases with higher systemic exposure. The drug's extensive plasma protein binding is documented as meaning that standard procedures like haemodialysis are not expected to significantly enhance Atorvastatin clearance.

Official Overdose Statements

  • Seek immediate medical attention for suspected overdose or the onset of severe symptoms (e.g., unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise).
  • Treatment requires the immediate discontinuation of Stacor.
  • Intensive clinical monitoring, including regular assessment of Creatine Kinase (CK) levels and Liver Function Tests (LFTs), is mandatory to monitor for systemic complications.

Connection to the Overall Overdose Profile

Regulatory documents define the Atorvastatin overdose profile by the mandate for immediate emergency intervention and the absence of a specific counteracting agent. The structure of post-overdose care is strictly defined by the need to monitor and manage the delayed, potentially life-threatening risks associated with muscle and liver toxicity.

Therapeutic Uses of Stacor

What Stacor Treats: Main Uses and Benefits

Stacor (Atorvastatin) is commonly used for managing symptoms related to systemic imbalance to support cardiovascular risk management. The focus is on sustained management of the blood lipid profile across key therapeutic domains.

The medication helps address symptom clusters that may become disruptive, specifically high Low-Density Lipoprotein (LDL) cholesterol and Triglycerides. It is primarily relevant for easing conditions characterized by periods of heightened symptoms of risk, including Primary Hypercholesterolemia, Mixed Dyslipidemia, and is applied in addressing the risk of major events such as heart attack or stroke in high-risk patients. It plays a role in managing severe inherited conditions such as Familial Hypercholesterolemia. This treatment is used for managing these systemic imbalances, which supports general well-being during symptomatic phases related to cardiovascular risk.


Quick Fact: Support for Systemic Imbalance

Stacor supports long-term vascular health by managing elevated LDL-C and triglyceride levels, which helps ease the overall symptom burden related to chronic arterial disease risk.

Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Stacor?

Official regulatory documentation for Stacor (Atorvastatin) establishes strict rules for eligibility based on age, physiological status, and underlying health conditions.


Contraindicated Populations

Classification Exclusionary Conditions
Absolute Exclusion Active liver disease or persistent, unexplained elevation of liver enzymes (>3 imes ULN)
Hypersensitivity Known allergy to atorvastatin or any component
Reproductive Status Pregnancy or Lactation (Breastfeeding)

Age and Conditional Use Rules

Population Group Eligibility Status (As Per Label)
Adults Approved for use across all indicated conditions.
Children Not indicated for treatment in patients below the age of 10 years.
Conditional Use Caution is required for patients with uncontrolled hypothyroidism, a history of liver disease or high alcohol consumption, and for those with hereditary muscular disorders or advanced age (ge 65 years).

Regulatory criteria mandate that women of child-bearing potential must use effective contraception due to the absolute contraindication during pregnancy. Renal impairment and advanced age are listed as predisposing factors for myopathy, requiring caution. Concomitant use with specific antiviral medications (e.g., glecaprevir/pibrentasvir) is also strictly prohibited.

What should I know about interactions with other medicines?

The official regulatory profile for Stacor is defined by strict constraints involving pharmacokinetic, pharmacodynamic, and substance interactions. Co-administration with Cyclosporine is designated as a contraindicated combination due to the substantial increase in Atorvastatin exposure, which raises the risk of myopathy and rhabdomyolysis. Certain antiviral combinations, including Tipranavir plus Ritonavir and Glecaprevir plus Pibrentasvir, should also be avoided due to similar severe interaction risks.

Pharmacokinetic interactions occur with strong CYP3A4 inhibitors, such as the antifungals Itraconazole and Ketoconazole and the antibiotic Clarithromycin. Co-use with these agents is officially stated to significantly elevate Atorvastatin plasma concentrations. Conversely, co-administration with inducers like St. John's Wort or Rifampin may reduce Stacor's effectiveness; for Rifampin, the timing rule mandates simultaneous administration to maintain adequate drug levels.

Pharmacodynamic interactions involve agents that share a risk of muscle toxicity. The combination with Fibric Acid Derivatives (e.g., Gemfibrozil) and lipid-modifying doses of Niacin ( 1 gram per day or higher) is documented to increase the cumulative risk of myopathy. Colchicine also belongs to this category of co-administered medicines.

In terms of product interactions, the consumption of grapefruit juice must be limited to less than 1.2 liters daily due to its effect of raising plasma concentrations. Additionally, Atorvastatin may officially increase the plasma levels of Oral Contraceptives (containing Norethindrone and Ethinyl Estradiol) and **Digoxin. Atorvastatin exposure is markedly increased in patients with documented hepatic impairment, which enhances the severity of concentration-dependent interactions.

Mechanism of Action

Dual-Action Control of Hepatic Lipid Metabolism

Stacor's mechanism begins with the selective competitive inhibition of the HMG-CoA reductase enzyme within the liver. This molecular blockade directly attenuates endogenous cholesterol synthesis in hepatocytes. The resulting reduction in intracellular cholesterol triggers a cellular compensatory response: the marked upregulation of LDL receptors on the hepatocyte surface. The downstream physiological effect is the enhanced clearance and removal of circulating LDL cholesterol from the bloodstream.


Vascular and Endothelial Pathway Modulation

The drug's action extends to pleiotropic effects mediated by the core pathway's inhibition, which reduces the supply of essential isoprenoid intermediates. This subsequently modulates intracellular signaling pathways that govern vessel function, specifically promoting the activity of endothelial Nitric Oxide Synthase (eNOS). This action contributes to the modulation of endothelial function and modulates local inflammatory signaling within the vascular system.


Mechanism Constraint: Receptor Dependence

The mechanism's maximal efficacy for systemic LDL removal is critically dependent on the functional integrity of the surface LDL Receptors. In biological states where these receptors are genetically deficient or impaired, the primary clearance mechanism is constrained, leading to reduced physiological capacity for systemic lipid reduction.

Dosage and Administration Information

Stacor is a prescription-only medicine supplied as film-coated tablets for oral administration. The medicine is available in four standardized strengths: 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.


Administration and Schedule

The use of Stacor is structured around a once-daily schedule, which can be flexibly administered as a single dose at any time of the day. The tablets can be taken with or without food. The standard adult regimen establishes a typical starting dose of 10 mg or 20 mg once daily, with the full official maintenance range extending up to 80 mg once daily. Dosage adjustments are officially directed to be assessed and implemented after 4 weeks or more following the start of therapy.


Procedural Rules and Adjustments

The film-coated tablets must be swallowed whole to ensure proper delivery of the active ingredient. If a dose is missed, regulatory guidelines instruct the patient to skip the missed dose and resume the regular schedule; a double dose must never be taken. Consumption of high volumes of grapefruit juice (specifically exceeding 1.2 liters per day) is officially advised against. For pediatric patients (10 to 17 years) being treated for Heterozygous Familial Hypercholesterolemia, the maximum dose is restricted to 20 mg once daily. No standard dose adjustment is necessary for patients based on renal function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Stacor


Evidence for Use in Primary Prevention of Cardiovascular Events

Research has studied Stacor's use in the primary prevention of a first cardiovascular event, relying heavily on large-scale Randomized Controlled Trials (RCTs) and systematic reviews. These studies were conducted on adults, typically between 40 and 75 years of age, who were identified as high-risk but had no pre-existing heart disease. Research examined patient data related to outcomes such as heart attacks, strokes, and the need for revascularization procedures. Limited information for long-term outcomes extending significantly beyond the primary trial durations remains a documented research gap.


Evidence for Use in Secondary Prevention of Cardiovascular Events

Research examined Stacor's use in patients who already have established Atherosclerotic Cardiovascular Disease (ASCVD), relying on many large-scale RCTs. Studies explored data related to the recurrence of Major Cardiovascular Events (MACE), including subsequent heart attacks and strokes, and also monitored outcomes linked to cardiovascular death and hospitalization for heart failure. Findings were observed in some studies to be associated with an increase in non-cardiac events leading to patient discontinuation when higher intensity regimens were used.


Evidence for Managing High Cholesterol and Mixed Dyslipidemia

Research examining Stacor's use for primary high cholesterol was evaluated in short-term Randomized Controlled Trials, primarily monitoring biomarker shifts (changes in blood fat concentrations). Findings describe patterns observed in the studies regarding the measured change in lipid biomarkers over short-term periods, typically eight to twelve weeks. The research exploring the prevention of clinical events in these low-risk groups is supported by evidence extrapolated from the longer-term primary and secondary prevention studies.


Evidence in Specific Patient Populations

Evidence for Pediatric Patients with Familial Hypercholesterolemia

Stacor was studied for use in children and adolescents, generally from age ten, diagnosed with Heterozygous Familial Hypercholesterolemia (HeFH). Research examined how measured lipid concentrations evolved over time. A documented limitation is that long-term effects are not fully established, and follow-up durations were limited in the core pediatric trials.


Research Gaps and Areas of Uncertainty

Areas where the data are still emerging or certainty remains low include specific therapeutic scenarios where comparative evidence is lacking, and where subgroup findings are uncertain. Specifically, long-term outcomes are not well characterized for patients with low or intermediate cardiovascular risk.

Key Studies & References NICE Guideline NG238: Lipid modification: Cardiovascular risk assessment and the modification of blood lipids

Frequently Asked Questions (FAQ)

Common questions about Stacor (FAQ)


Q: How quickly should a person expect to see the effects of Stacor?

A: Studies show that Stacor begins to lower lipid levels within the first two weeks after starting treatment. The maximum therapeutic effect, which is the full reduction in cholesterol, is typically observed after two to four weeks. This timeframe is recognized in official documents for the reassessment of the medicine’s effects.

Q: Can Stacor cause any weight changes, like gain or loss?

A: Official documentation lists weight gain as an uncommon side effect, meaning it occurs in fewer than 1 in 100 patients. Weight loss is not specifically noted in the official classifications of common or uncommon side effects for this medication.

Q: Is it normal to feel dizzy or tired when starting Stacor?

A: Dizziness and fatigue (tiredness) are both listed in official sources as uncommon side effects, reported by less than 1% of patients. However, headache is classified as common in the official classifications.

Q: Does Stacor interact with cold and flu medications?

A: Stacor has the potential to interact with many medicines, especially those that affect the body's CYP3A4 enzyme system. While official warnings do not list all cold and flu products specifically, the official label advises considering the potential for interaction with medicines that affect the CYP3A4 enzyme, including certain components found in other products.

Q: Are there specific food types that must be eaten with Stacor to help absorption?

A: According to official product information, Stacor can be taken effectively either with or without food. Although food may slightly alter the speed at which the active ingredient is absorbed into the bloodstream, the overall lipid-lowering efficacy remains the same whether it is taken on an empty stomach or with a meal.

Q: What is the purpose of the different strengths of Stacor tablets?

A: The tablets come in different strengths (10 mg, 20 mg, 40 mg, and 80 mg) to allow for personalized dosing. The goal is to select the strength required to achieve the patient's individual lipid reduction target, which is detailed in the official prescribing information.

Q: What is the difference between Stacor and [Name of common competing drug]?

A: Stacor is classified in the pharmacological group known as statins, which are medicines that work by blocking the HMG-CoA reductase enzyme to lower cholesterol. Official regulatory documents focus on Stacor's specific actions and do not make comparative statements about its effectiveness or safety profile versus other drugs in the same class.

Q: Can Stacor cause insomnia or changes in sleep patterns?

A: Insomnia (difficulty sleeping) is listed in official documentation as an uncommon side effect. Additionally, the occurrence of nightmares is also classified as an uncommon effect reported by patients taking the medication.

Q: Can Stacor affect cholesterol or blood sugar levels?

A: Stacor's primary purpose is to lower high cholesterol levels. However, hyperglycemia (high blood sugar) is listed as a common side effect. Regulatory documents state that statin labels include a warning about a modest increased risk of new-onset diabetes.

Q: Does Stacor affect a person's ability to drive or operate machinery?

A: Official information states that Stacor has a negligible influence on the ability to drive or use complex machinery. Official guidance notes that caution may be necessary if a patient experiences side effects like dizziness.

Q: Does Stacor interact with birth control pills?

A: The official product label indicates that taking Stacor concurrently may increase the plasma concentration of certain ingredients found in oral contraceptives, specifically norethindrone and ethinyl estradiol. This change in concentration is noted in regulatory documents for consideration.

Q: How is Stacor removed from the body?

A: Stacor and its active breakdown products are eliminated from the body primarily through the bile, after being processed by the liver and other tissues. Only a minimal amount (less than 2%) of the medicine is recovered in the urine.

Q: Does Stacor contain any common allergens like gluten or lactose?

A: The official product documentation (SmPC) lists lactose monohydrate as a non-active ingredient (excipient) in the tablet formulation. This information is important for patients with specific lactose sensitivities.

Q: Can Stacor cause dry mouth or changes in taste?

A: Changes in taste, known as dysgeusia, are listed in official documentation as an uncommon side effect. Dry mouth is not classified in the official listing of common or uncommon adverse reactions for this medication.

Q: Is Stacor used to prevent a condition, or is it only for treatment?

A: Official indications show that Stacor is approved for both purposes. It is used as a treatment for high cholesterol and is also indicated for the primary and secondary prevention of cardiovascular events, such as heart attacks and strokes, in adult patients identified as high risk.

Q: Why do some patients report headaches when they first start Stacor?

A: Headache is classified in official documentation as a common side effect, meaning it is reported by 1 in 100 to 1 in 10 patients in clinical trials. The occurrence of a headache is a recognized effect that has been observed during the initial phase of therapy.

Q: Can Stacor affect fertility in men or women?

A: Official sources state that there is no clear evidence to suggest that this medication reduces fertility in either men or women. Regulatory criteria require women of child-bearing potential to use effective contraception due to the absolute contraindication of the drug during pregnancy.

How should Stacor be stored and disposed of?

Stacor (atorvastatin) must be stored strictly according to the conditions defined in the official regulatory labeling to maintain stability.

Required Storage Conditions

Condition Type Requirement (Regulatory Wording)
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), protected from excessive heat.
Container & Handling Keep the medicine in the original container and ensure the container is tightly closed.
Environmental Store away from excess moisture; avoid humid areas like the bathroom.

Child-Safety and Disposal

The tablets must be kept out of the sight and reach of children, with all safety caps locked. Regarding disposal, Stacor is not on the FDA's flush list and must not be flushed down the toilet. Unused or expired medication must be disposed of in accordance with local requirements, typically by utilizing a drug take-back program or following the recommended household trash disposal method for non-flush drugs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stacor found in:

A-Z Index: